PE20240225A1 - Anticuerpos anti-cd48, conjugados de anticuerpo-farmaco, y usos de los mismos - Google Patents
Anticuerpos anti-cd48, conjugados de anticuerpo-farmaco, y usos de los mismosInfo
- Publication number
- PE20240225A1 PE20240225A1 PE2023001713A PE2023001713A PE20240225A1 PE 20240225 A1 PE20240225 A1 PE 20240225A1 PE 2023001713 A PE2023001713 A PE 2023001713A PE 2023001713 A PE2023001713 A PE 2023001713A PE 20240225 A1 PE20240225 A1 PE 20240225A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- antibody
- antibodies
- cdrs
- hcdr1
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title abstract 2
- 229940049595 antibody-drug conjugate Drugs 0.000 title abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 2
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 239000002254 cytotoxic agent Substances 0.000 abstract 1
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 102000046585 human CD48 Human genes 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La invencion esta referida a anticuerpos o fragmentos de union a antigeno de los mismos, que se unen a CD48 humana (anti CD-48) que comprende tres CDR de la cadena pesada y tres CDR de la cadena ligera: (i) laHCDR1 que consiste en la SEQ ID NO: 1, la HCDR2 que consiste en la SEQ ID NO: 2, la HCDR3 que consiste en la SEQ ID NO: 3, la LCDR1 que consiste en la SEQ ID NO: 16, la LCDR2 que consiste en la SEQ ID NO: 17, y la LCDR3 que consiste en la SEQ ID NO: 18; (ii) la HCDR1 que consiste en la SEQ ID NO: 4, la HCDR2 que consiste en la SEQ ID NO: 2, la HCDR3 que consiste en la SEQ ID NO: 3; LCDR1 que consiste en la SEQ ID NO: 16, la LCDR2 que consiste en la SEQ ID NO: 17 y la LCDR3 que consiste en la SEQ ID NO: 18, entre otros. Asimismo, divulga un conjugado de anticuerpo-farmaco de formula: A-(LB-(D)n)y; en donde: A es el citado un anticuerpo anti-CD-48; LB es un enlazador; D es un agente citotoxico; n es un entero entre 1 y 10, y es un entero entre 1 y 10. Tambien se refiere a un modo de elaboracion del anticuerpo y a una composicion farmaceuticas que los comprenden, siendo utiles en el tratamiento de cancer
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063117817P | 2020-11-24 | 2020-11-24 | |
PCT/IB2021/060871 WO2022112942A2 (en) | 2020-11-24 | 2021-11-23 | Anti-cd48 antibodies, antibody drug conjugates, and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20240225A1 true PE20240225A1 (es) | 2024-02-16 |
Family
ID=78819811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2023001713A PE20240225A1 (es) | 2020-11-24 | 2021-11-23 | Anticuerpos anti-cd48, conjugados de anticuerpo-farmaco, y usos de los mismos |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP4251648A2 (es) |
JP (1) | JP2023549925A (es) |
KR (1) | KR20230112128A (es) |
CN (1) | CN116615252A (es) |
AR (1) | AR124139A1 (es) |
AU (1) | AU2021388021A1 (es) |
CA (1) | CA3200858A1 (es) |
CL (1) | CL2023001483A1 (es) |
CO (1) | CO2023008051A2 (es) |
CR (1) | CR20230283A (es) |
DO (1) | DOP2023000102A (es) |
EC (1) | ECSP23045888A (es) |
IL (1) | IL303059A (es) |
MX (1) | MX2023006010A (es) |
PE (1) | PE20240225A1 (es) |
TW (1) | TW202237650A (es) |
UY (1) | UY39533A (es) |
WO (1) | WO2022112942A2 (es) |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
JPH06507404A (ja) | 1991-05-01 | 1994-08-25 | ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン | 感染性の呼吸性疾患の治療方法 |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
ES2149768T3 (es) | 1992-03-25 | 2000-11-16 | Immunogen Inc | Conjugados de agentes enlazantes de celulas derivados de cc-1065. |
AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
US6132764A (en) | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
ATE508733T1 (de) | 1996-03-04 | 2011-05-15 | Penn State Res Found | Materialien und verfahren zur steigerung der zellulären internalisierung |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
ES2236832T3 (es) | 1997-01-16 | 2005-07-16 | Massachusetts Institute Of Technology | Preparacion de particulas para inhalacion. |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
ES2301198T3 (es) | 1997-06-12 | 2008-06-16 | Novartis International Pharmaceutical Ltd. | Polipeptidos artificiales de anticuerpos. |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
AU747231B2 (en) | 1998-06-24 | 2002-05-09 | Alkermes, Inc. | Large porous particles emitted from an inhaler |
NZ517772A (en) | 1999-11-24 | 2004-03-26 | Immunogen Inc | Cytotoxic agents comprising taxanes and their therapeutic use |
ES2274823T3 (es) | 1999-12-29 | 2007-06-01 | Immunogen, Inc. | Agentes cototoxicos que comprenden doxorrubicinas y daunorrubicinas y su utilizacion terapeutica. |
GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
ATE395413T1 (de) | 2001-12-03 | 2008-05-15 | Amgen Fremont Inc | Antikörperkategorisierung auf der grundlage von bindungseigenschaften |
EP1577288B1 (en) | 2002-12-26 | 2014-07-23 | Eisai R&D Management Co., Ltd. | Selective estrogen receptor modulators |
SG10201701737XA (en) * | 2003-11-06 | 2017-04-27 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
US20090304721A1 (en) | 2005-09-07 | 2009-12-10 | Medlmmune, Inc | Toxin conjugated eph receptor antibodies |
RU58668U1 (ru) | 2006-06-05 | 2006-11-27 | Открытое акционерное общество "Нижегородский машиностроительный завод" | Водогрейный котел |
PE20110218A1 (es) | 2006-08-02 | 2011-04-01 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
KR20210100223A (ko) | 2008-04-30 | 2021-08-13 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
JO2924B1 (en) | 2008-08-22 | 2015-09-15 | نوفارتيس ايه جي | Pyroloperimidine compounds and their uses |
CA2757941C (en) * | 2009-04-10 | 2016-02-23 | Osaka University | Therapeutic agent for diseases in which neoplastic proliferation of plasma cells occurs |
US20120213705A1 (en) | 2009-06-22 | 2012-08-23 | Medimmune, Llc | ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION |
US8795135B2 (en) | 2009-09-01 | 2014-08-05 | Ford Global Technologies, Llc | Method for controlling an engine during a restart |
US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
EP3205648A1 (en) | 2010-06-10 | 2017-08-16 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
WO2011159769A2 (en) | 2010-06-17 | 2011-12-22 | Aragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
AR083044A1 (es) * | 2010-09-27 | 2013-01-30 | Regeneron Pharma | Anticuerpos anti-cd48 y usos de los mismos |
US20140065590A1 (en) | 2012-02-20 | 2014-03-06 | Knowre Korea Inc | Method, system, and computer-readable recording medium for providing education service based on knowledge units |
JP6321633B2 (ja) | 2012-06-04 | 2018-05-09 | ノバルティス アーゲー | 部位特異的標識法およびそれによって生成される分子 |
AU2014214751B2 (en) | 2013-02-08 | 2017-06-01 | Novartis Ag | Specific sites for modifying antibodies to make immunoconjugates |
TR201806882T4 (tr) | 2013-02-19 | 2018-06-21 | Novartis Ag | Selektif östrojen reseptörü yıkıcıları olarak benzotiofen türevleri ve bunların bileşimleri. |
US20170021033A1 (en) | 2014-03-12 | 2017-01-26 | Novartis Ag | Specific sites for modifying antibodies to make immunoconjugates |
EP3116496A1 (en) | 2014-03-13 | 2017-01-18 | F. Hoffmann-La Roche AG | Methods and compositions for modulating estrogen receptor mutants |
US10722592B2 (en) * | 2015-03-18 | 2020-07-28 | Seattle Genetics, Inc. | CD48 antibodies and conjugates thereof |
TW202014209A (zh) * | 2018-06-20 | 2020-04-16 | 瑞士商諾華公司 | 用於消融造血幹細胞之抗體藥物軛合物 |
CN110835316A (zh) * | 2018-08-17 | 2020-02-25 | 中国人民解放军军事科学院军事医学研究院 | 连接子、含连接子的抗体偶联药物及连接子的用途 |
-
2021
- 2021-11-23 MX MX2023006010A patent/MX2023006010A/es unknown
- 2021-11-23 CA CA3200858A patent/CA3200858A1/en active Pending
- 2021-11-23 JP JP2023530586A patent/JP2023549925A/ja active Pending
- 2021-11-23 PE PE2023001713A patent/PE20240225A1/es unknown
- 2021-11-23 IL IL303059A patent/IL303059A/en unknown
- 2021-11-23 AU AU2021388021A patent/AU2021388021A1/en active Pending
- 2021-11-23 EP EP21816541.3A patent/EP4251648A2/en active Pending
- 2021-11-23 CR CR20230283A patent/CR20230283A/es unknown
- 2021-11-23 CN CN202180077385.XA patent/CN116615252A/zh active Pending
- 2021-11-23 WO PCT/IB2021/060871 patent/WO2022112942A2/en active Application Filing
- 2021-11-23 KR KR1020237020382A patent/KR20230112128A/ko unknown
- 2021-11-24 TW TW110143728A patent/TW202237650A/zh unknown
- 2021-11-24 AR ARP210103245A patent/AR124139A1/es unknown
- 2021-11-24 UY UY0001039533A patent/UY39533A/es unknown
-
2023
- 2023-05-22 DO DO2023000102A patent/DOP2023000102A/es unknown
- 2023-05-23 CL CL2023001483A patent/CL2023001483A1/es unknown
- 2023-06-21 EC ECSENADI202345888A patent/ECSP23045888A/es unknown
- 2023-06-21 CO CONC2023/0008051A patent/CO2023008051A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
IL303059A (en) | 2023-07-01 |
ECSP23045888A (es) | 2023-07-31 |
WO2022112942A3 (en) | 2022-07-14 |
MX2023006010A (es) | 2023-06-08 |
DOP2023000102A (es) | 2023-07-31 |
EP4251648A2 (en) | 2023-10-04 |
TW202237650A (zh) | 2022-10-01 |
CR20230283A (es) | 2023-07-27 |
KR20230112128A (ko) | 2023-07-26 |
AR124139A1 (es) | 2023-02-15 |
CL2023001483A1 (es) | 2024-01-05 |
CO2023008051A2 (es) | 2023-07-10 |
AU2021388021A1 (en) | 2023-06-22 |
UY39533A (es) | 2022-06-30 |
JP2023549925A (ja) | 2023-11-29 |
CA3200858A1 (en) | 2022-06-02 |
WO2022112942A2 (en) | 2022-06-02 |
US20220162308A1 (en) | 2022-05-26 |
CN116615252A (zh) | 2023-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20231049A1 (es) | Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso | |
HRP20180015T1 (hr) | Anti-mezotelinski imunokonjugati i njihova uporaba | |
PE20220218A1 (es) | Conjugados de anticuerpo-farmaco inhibidores de mcl-1 y sus metodos de uso | |
PE20240814A1 (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso | |
NZ583605A (en) | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses | |
PE20210045A1 (es) | Anticuerpos agonistas contra pd-1 y usos de estos | |
AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
PE20100251A1 (es) | Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina | |
CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
PE20210132A1 (es) | Anticuerpos anti-cd3 y usos de estos | |
PE20212088A1 (es) | Anticuerpos anti-tau y uso de los mismos | |
PE20160712A1 (es) | Anticuerpos e inmunoconjugados anti-cd33 | |
NZ599777A (en) | Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) | |
PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
CU24636B1 (es) | Anticuerpos que reconocen tau en los residuos 257-271 o 320-334 de la seq id no: 1 | |
AR091702A1 (es) | Anticuerpos anti-cd79b e inmunoconjugados | |
PE20061166A1 (es) | Moleculas de anticuerpo que tienen especificidad para la il-17 humana | |
RU2018123717A (ru) | Комбинированные лечения, их применения и способы | |
PE20150159A1 (es) | Composiciones y metodos para anticuerpos que actuan sobre el factor p | |
MX2020011554A (es) | Composiciones y metodos relacionados con conjugados de farmacos de anticuerpo anti grupo de diferenciacion 19 (cd19). | |
MX2021010003A (es) | Anticuerpos anti-mertk de alta afinidad y usos de los mismos. | |
JP2016538318A5 (es) | ||
AR123480A1 (es) | Moléculas de unión terapéuticas | |
WO2018119196A8 (en) | Immunoconjugates targeting adam9 and methods of use thereof | |
PE20201255A1 (es) | Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos |